PREPARATION AND IN-VITRO EVALUATION OF MOUTH DISSOLVING TABLETS OF METOCLOPRAMIDE HYDROCHLORIDE
Dr. Shivanand Kalyanappa*, Dr. Ali Khodayarlou, Dr. Anirbandeep Bose, Dr. Dana Bayemaninezhad and Dr. Divakar Goli
ABSTRACT
This study was aimed at development of metoclopramide hydrochloride mouth dissolving tablets (MDTs) which can disintegrate or dissolve rapidly once placed in the oral cavity. Metoclopramide hydrochloride is a dopamine D2 receptors antagonist and a mixed 5- HT3 receptor antagonist/5-HT4 receptor agonist used in the treatment of nausea and vomiting associated with uremia, radiation sickness, cancer and the effects of chemotherapy, labor, infection, migraine headaches, and emetogenic drugs. The objective of this study is to prepare MDTs containing metoclopramide hydrochloride using various superdisintegrant such as sodium starch glycolate and croscarmellose sodium by direct compression method in different concentrations. The final blend was evaluated for bulk density, tapped density, carrʼs index, angle of repose and Hausnerʼs ratio. The compressed MDTs were evaluated for hardness, thickness, weight variation, friability, in-vitro disintegration time, wetting time, drug content, in-vitro drug release studies, kinetic studies and short term stability studies. Among the formulations, the formulation (F6) containing croscarmellose sodium (CCS) considered as satisfactory product showed minimum disintegration time of 35.33 sec, in-vitro dissolution study showed maximum % cumulative drug release (CDR) of 99.15%. Kinetic studies of dissolution data displayed zero order model, IR spectra studies revealed the absence of drug polymer reaction, and short term stability studies for two months were shown absence of significant changes in some aspects of tablets.
Keywords: Metoclopramide hydrochloride; Nausea and vomiting; Mouth dissolving tablets (MDTs); Superdisintegrants.
[Download Article]
[Download Certifiate]